Less is more: a cost benefit analysis of a changed posology for nivolumab

Eur J Clin Pharmacol. 2020 May;76(5):739-740. doi: 10.1007/s00228-020-02839-7. Epub 2020 Jan 28.

Authors

N W Boone¹, A A van Bodegraven²

Affiliations

¹ Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, PO Box 5500, NL 6130 MB, Sittard-Geleen / Heerlen, The Netherlands. [email protected].
² Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen / Heerlen, The Netherlands.

PMID: 31993685
DOI: 10.1007/s00228-020-02839-7

No abstract available

Publication types

Letter

MeSH terms

Cost-Benefit Analysis*
Humans
Neoplasms / drug therapy*
Neoplasms / economics*
Nivolumab / administration & dosage*
Nivolumab / economics*

Substances

Nivolumab